Larimar Therapeutics Q3 net loss narrows as R&D expenses fall
LRMR•Larimar Therapeutics reported a third-quarter net loss of $31.14 million, or $0.29 per share, as research and development expenses fell. It ended the quarter with $128.7 million in cash and equivalents and projected a cash runway into late Q2 2027.
1. Quarterly results
Larimar’s third-quarter net loss narrowed year over year as research and development expenses fell, mainly due to a $19.3 million decrease in drug manufacturing activities at third-party manufacturers. General and administrative expenses rose as the company increased commercial consulting, legal and compensation costs while preparing for a potential nomlabofusp launch.
2. Nomlabofusp plans
The company completed its BLA submission for nomlabofusp, seeking accelerated approval for Friedreich’s ataxia. Larimar expects FDA review and progress in its Phase 3 study over the next 12 months, and is preparing for a potential U.S. launch in Q3 2027 if the drug is approved.




